abciximab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
chimeric origin 4950 143653-53-6

Description:

MoleculeDescription

Synonyms:

  • abciximab
  • reopro
  • 7E3
A Fab fragment of the chimeric monoclonal antibody 7E3 that binds to the glycoprotein IIb-IIIa receptor of human platelets, and blocks PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX, potently inhibiting PLATELET AGGREGATION. It is used in treatment of refractory unstable angina, and for prevention of ischemic complications in patients undergoing percutaneous coronary procedures such as ANGIOPLASTY; ATHERECTOMY; or stenting.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
25 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
Dec. 16, 1993 FDA CENTOCOR INC

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombocytopenia 104.17 76.13 46 386 190233 42430670
Oesophageal ulcer haemorrhage 76.59 76.13 11 421 372 42620531

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombocytopenia 124.05 89.85 54 630 348831 110239784
Vascular stent thrombosis 93.62 89.85 17 667 4144 110584471

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC B01AC13 BLOOD AND BLOOD FORMING ORGANS
ANTITHROMBOTIC AGENTS
ANTITHROMBOTIC AGENTS
Platelet aggregation inhibitors excl. heparin
MeSH PA D000925 Anticoagulants
MeSH PA D006401 Hematologic Agents
MeSH PA D010975 Platelet Aggregation Inhibitors
CHEBI has role CHEBI:35554 cardiovascular drug
CHEBI has role CHEBI:50249 anticoagulant

Related Drugs by ATC class:

B01AC Platelet aggregation inhibitors excl. heparin 24 drugs
acetylsalicylic acidaloxiprinberaprostcangrelorcarbasalate calciumcilostazolclopidogrelcloricromendipyridamoleditazoleepoprostenoleptifibatide show all 24 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Percutaneous coronary intervention indication 415070008




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Integrin alpha-IIb/beta-3 Adhesion ANTIBODY BINDING DRUG LABEL DRUG LABEL

External reference:

IDSource
D02778 KEGG_DRUG
4020901 VUID
N0000148393 NUI
4020901 VANDF
CHEBI:749549 CHEBI
CHEMBL1201584 ChEMBL_ID
6584 IUPHAR_LIGAND_ID
DB00054 DRUGBANK_ID
152293 RXNORM
1007 MMSL
4116 MMSL
d03811 MMSL
004907 NDDF
108974006 SNOMEDCT_US
386951001 SNOMEDCT_US
C0288672 UMLSCUI
D000077284 MESH_DESCRIPTOR_UI
7200 INN_ID
X85G7936GV UNII

Pharmaceutical products:

None